Michael G. Kauffman, MD, PhD, has resigned his position as CEO and a director of EPIX Pharmaceuticals, to pursue other opportunities.
The Lexington, Mass-based EPIX’s board of directors Monday named Elkan Gamzu, PhD, as interim CEO.
Kauffman joined EPIX in August 2006 in connection with its acquisition of Predix Pharmaceuticals Holdings, where he had served as CEO since September 2002, according to EPIX.
Gamzu is currently a consultant to the biotechnology and pharmaceutical industries and has held a number of executive positions in the industries including: CEO of Pharmos; vice president of project management leadership at Millennium Pharmaceuticals; CEO of Cambridge Neuroscience; vice president of drug development at Warner-Lambert; and senior positions with Hoffmann-La Roche, EPIX said.
Earlier this month, EPIX resubmitted its new drug application for its blood pool MR angiography agent, Vasovist, to the FDA.